109 related articles for article (PubMed ID: 3435602)
1. [Plasma level and action of sotalol-HCL on the ECG interval after parenteral administration in healthy subjects].
Rehm KD; Schnelle K; Dyde CJ; Blümner E; Arendts W
Arzneimittelforschung; 1987 Sep; 37(9):1058-62. PubMed ID: 3435602
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.
Barbey JT; Sale ME; Woosley RL; Shi J; Melikian AP; Hinderling PH
Clin Pharmacol Ther; 1999 Jul; 66(1):91-9. PubMed ID: 10430114
[TBL] [Abstract][Full Text] [Related]
3. [Electrophysiological effects of intravenous sotalol. Relation with plasma levels].
Dumoulin P; Weissenburger J; Poirier JM; Rosensztajn L; Gallet B; Jaillon P; Têtard C; Cheymol G; Valty J
Arch Mal Coeur Vaiss; 1985 Apr; 78(4):562-8. PubMed ID: 3923983
[TBL] [Abstract][Full Text] [Related]
4. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans.
Funck-Brentano C; Kibleur Y; Le Coz F; Poirier JM; Mallet A; Jaillon P
Circulation; 1991 Feb; 83(2):536-45. PubMed ID: 1846784
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.
Saul JP; Ross B; Schaffer MS; Beerman L; Melikian AP; Shi J; Williams J; Barbey JT; Jin J; Hinderling PH;
Clin Pharmacol Ther; 2001 Mar; 69(3):145-57. PubMed ID: 11240979
[TBL] [Abstract][Full Text] [Related]
6. Investigating the effect of sotalol on the repolarization intervals in healthy young individuals.
Couderc JP; Zhou M; Sarapa N; Zareba W
J Electrocardiol; 2008; 41(6):595-602. PubMed ID: 18801493
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oral sotalol in suppression of premature ventricular complexes and analysis of its beta-adrenergic blocking activity.
Giorgi C; Nadeau R; Agha A; Primeau R; de Champlain J
Can J Cardiol; 1990 Jun; 6(5):191-7. PubMed ID: 1696514
[TBL] [Abstract][Full Text] [Related]
8. The safety and tolerability of single intravenous doses of lubeluzole (Prosynap) in healthy volunteers.
Hantson L; Tritsmans L; Crabbé R; Gheuens J; Van Rooy P
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):491-5. PubMed ID: 9401829
[TBL] [Abstract][Full Text] [Related]
9. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers.
Sardina M; Love R; Mizrahi J; Monzani V; Bianchini C
J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S72-9. PubMed ID: 8839230
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z; Grasela DM; Krishna G
Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
[TBL] [Abstract][Full Text] [Related]
12. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
13. Investigations into the bradycardic action of indoramin.
Lillie C; Harron DW; Kobinger W
Arzneimittelforschung; 1985; 35(1A):301-5. PubMed ID: 4039170
[TBL] [Abstract][Full Text] [Related]
14. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol.
Somberg JC; Preston RA; Ranade V; Molnar J
Cardiology; 2010; 116(3):219-25. PubMed ID: 20693799
[TBL] [Abstract][Full Text] [Related]
15. [Sotalol, propafenone, and flecainide: compared multiparametric analysis of ventricular repolarization in subjects without organic cardiopathy].
Sarubbi B; Ducceschi V; Briglia N; Esposito R; Mayer MS; Scialdone A; Santangelo L; Iacono A
Cardiologia; 1996 Jul; 41(7):645-51. PubMed ID: 8983831
[TBL] [Abstract][Full Text] [Related]
16. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
Milic M; Bao X; Rizos D; Liu F; Ziegler MG
Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
Brode E; Müller-Peltzer H; Hollmann M
Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.
Sen L; Cui G; Sakaguchi Y; Singh BN
J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
[TBL] [Abstract][Full Text] [Related]
20. Influence of age, the autonomic nervous system and anxiety on QT-interval variability.
Piccirillo G; Cacciafesta M; Lionetti M; Nocco M; Di Giuseppe V; Moisè A; Naso C; Marigliano V
Clin Sci (Lond); 2001 Oct; 101(4):429-38. PubMed ID: 11566081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
